GlassScriptPhysician profile
Mario A Sanchez
NPI 1205804911
$4,364.95
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $617 · 2021: $962 · 2022: $1,188 · 2023: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368 · Education: $47.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.54 |
| Education | $47.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.74 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $410.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.24 | 2019-2023 | Jardiance |
| Amgen INC. | $406.36 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $385.32 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $281.99 | 2019-2022 | |
| Abbvie INC. | $281.05 | 2021-2023 | Vraylar |
| Pfizer INC. | $279.15 | 2019-2022 | |
| Lilly USA, LLC | $231.30 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $184.49 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $145.87 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $130.16 | 2019-2022 | |
| Genentech USA, INC. | $90.87 | 2019-2021 | |
| Vifor Pharma, INC. | $86.17 | 2021 | |
| Glaxosmithkline, LLC. | $62.07 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $55.82 | 2021-2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $50.64 | 2021 | |
| Radius Health, INC. | $47.40 | 2023 | Tymlos |
| Paratek Pharmaceuticals, INC. | $33.28 | 2022 | |
| Allergan, INC. | $32.02 | 2020 | |
| Esperion Therapeutics, INC. | $31.55 | 2021-2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.61 | 2021-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $27.42 | 2023 | Rexulti |
| Mannkind Corporation | $15.98 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.82 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $11.51 | 2021 | |
| Fidia Pharma USA INC. | $3.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.